What Lumea does

Lumea is a U.S.-headquartered (Lehi, Utah) digital pathology company founded in 2013 that sells a specialty-specific platform covering the full diagnostic workflow from biopsy to final report, serving urology, dermatopathology, and gastroenterology laboratories. The platform is built around four components: the FDA 510(k)-cleared IMS Viewer+ for primary clinical diagnosis, BxLink (a digital pathology-enabled LIS for case management and molecular test ordering), a proprietary tissue-handling portfolio (BxBoard, BxChip, BxCamera, BxFrame, FocalRing) that improves specimen quality at the point of collection, and an open Partner Marketplace integrating third-party AI tools, molecular tests, scanners, and lab technology. The company reports more than 40% share of the U.S. outpatient prostate cancer diagnostics market and a customer base of hundreds of labs ranging from single-pathologist offices to nationwide networks, with GI Alliance (the nation's largest GI network) cited as a flagship deployment.

Lumea generates revenue through a mix of recurring software subscriptions (IMS Viewer+, BxLink), hardware and consumables sales (BxBoard, BxChip, BxCamera tissue-handling products), and a marketplace model that monetizes third-party AI and molecular test integrations within the diagnostic workspace. Go-to-market is primarily enterprise field sales with a 'Request Information' demo-led acquisition motion and 3-9 month implementation timelines, supplemented by a North America e-commerce shop, a separate Europe catalog, and an international distributor network. Pricing is quote-based and not publicly disclosed, with the company claiming typical customer ROI within three months of full-platform implementation.

Strategically, Lumea has aggressively expanded its AI and workflow footprint through partnerships with Voicebrook (voice-enabled documentation, announced 2026-02-11), Primaa (Cleo Skin AI for dermatopathology, 2026-03-24), and AIxMed (AIxURO urine cytology AI for urology, 2025-05-30), positioning itself as a platform-of-record rather than a point viewer. Recognition on Inc. 5000, Fast 500, Fast 50, and a favorable KLAS Research customer satisfaction finding versus traditional imaging vendors underscore commercial traction, though no revenue figure, funding history, or headcount detail beyond the 11-50 range is disclosed in the available data.

Name

Lumea

Legal name

Lumea

Website

https://lumea.net

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Lumea is a Lehi, Utah-based digital pathology company that provides an FDA-cleared platform covering biopsy-to-diagnosis for urology, dermatopathology, and gastroenterology labs, serving hundreds of practices including the nation's largest GI network.

Ownership category

akta.pro rank

Product category

Digital Pathology Software and Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)

SIC

Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB)

akta.pro secondary industries

Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ), Laboratory Informatics for Diagnostics (LIS/Middleware/Analyzer Connectivity) (HLAHAAAO), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Digital pathology platform
• Whole slide imaging
• Pathology laboratory software
• Biopsy tissue technology
• Diagnostic AI marketplace

Headquarters

HQ city

Lehi

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Digital Pathology Software Platform: Subscription-based revenue from FDA-cleared IMS Viewer+ platform providing whole slide imaging diagnostic capabilities. Labs recover investment within three months through efficiency gains, reduced shipping/courier costs, lower slide storage expenses, and fewer repeat procedures.
2. Tissue-Handling Technology: Hardware and consumables revenue from BxBoard, BxChip, BxCamera, and related tissue technology products. Provides immediate ROI within three months of implementation through improved specimen quality and reduced diagnostic errors.
3. Laboratory Information System (BxLink): LIS software revenue for complete case management and molecular test ordering integrated with digital pathology workflow.
4. Partner Marketplace: Revenue from integration of third-party AI tools and molecular tests into Lumea's platform ecosystem, expanding diagnostic capabilities for pathology labs.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Core offering

Lumea provides a specialty-specific digital pathology platform covering the full biopsy-to-diagnosis workflow. Its core offerings include the FDA 510(k)-cleared IMS Viewer+ for whole slide imaging, the BxLink digital pathology-enabled LIS, proprietary tissue-handling devices (BxBoard, BxChip, BxCamera, BxFrame), and an open Partner Marketplace that embeds third-party AI, molecular tests, and scanners directly into the diagnostic workspace. The platform is purpose-built for urology, dermatopathology, and gastroenterology practices.

Product overview

Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow from biopsy to final report. The platform operates as a unified platform-plus-modules architecture with four core components: (1) IMS Viewer+ - an FDA 510(k)-cleared digital pathology viewer for full diagnostic capability on any device; (2) BxLink - an all-in-one digital pathology-enabled LIS for case management and molecular test ordering; (3) Tissue-handling and histology technology (BxBoard, BxChip, BxCamera) that improves specimen quality and workflow efficiency starting at the point of collection; and (4) An open AI ecosystem via the Partner Marketplace that lets labs integrate AI tools from partners including Paige, Primaa, Mindpeak, and AIRA Matrix directly into the diagnostic workspace. The platform is designed for specialty-specific workflows in urology (particularly prostate cancer diagnostics, supporting over 40% of the U.S. outpatient market), dermatopathology, and gastroenterology.

Differentiator

Problem solved

Functional benefit

Brands

• IMS Viewer+: FDA-cleared digital pathology viewer for primary clinical diagnosis
• BxLink
• BxBoard
• BxCamera
• BxChip

Products and services

• IMS Viewer+ FDA 510(k)-cleared digital pathology viewer for primary clinical diagnosis using whole slide images. Provides lightning-fast, closest-to-glass performance with seamless access to AI and molecular testing on one screen, compatible with images from all major scanner manufacturers, and configurable for urology, dermatopathology, and gastroenterology workflows.
• BxLink Digital pathology-enabled Laboratory Information System (LIS) that manages case intake, image routing, AI result integration, molecular test ordering, and report generation in a single workspace for pathology labs; not approved by the FDA for digital primary diagnosis.
• BxBoard Precision tissue collection device for physicians and medical assistants that preserves specimen integrity, minimizes fragmentation, and improves diagnostic yield; available in prostate biopsy ('The Better Biopsy') and bladder (FocalRing) configurations.
• BxCamera Better Grossing lab technology for pathologists' assistants and histotechs that enables digital grossing documentation, reduces errors, accelerates turnaround, and maximizes lab productivity and revenue.
• BxChip Prostate tissue collection chip for the laboratory workflow that preserves specimen quality and supports efficient tissue handling during processing.
• BxFrame Gastrointestinal tissue handling technology for improved tissue handling and specimen quality in GI diagnostics.
• Partner Marketplace Open AI ecosystem and marketplace allowing labs to integrate best-in-class AI tools (Paige, Primaa, Mindpeak, AIRA Matrix, AIxMed), molecular tests, scanners, and lab technology partners directly into the diagnostic workspace without changing existing LIS or scanning hardware.

Quantifiable outcome

• 19% increase in cancer detection rates
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability3 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered core and flagship.

• PrimaacoreTechnology or Integration · 24 March 2026Partnership to integrate Primaa's Cleo Skin AI solution into Lumea's FDA-cleared IMS Viewer+ platform for dermatopathology diagnostics. Cleo Skin is the first AI tool worldwide designed specifically to assist in diagnosing the four most common skin lesions, offering automated triage, sub-millimeter measurements, and biomarker detection. The open marketplace integration allows labs to adopt the technology without changing their existing LIS or scanning hardware, expanding Lumea's diagnostic ecosystem for dermatology groups.
• VoicebrookcoreTechnology or Integration · 11 February 2026Strategic partnership integrating Voicebrook's VoiceOver PRO platform with Lumea's digital pathology ecosystem including BxCamera and BxLink. The collaboration enables hands-free documentation, image capture, and structured reporting workflows for pathology labs, spanning from grossing through final sign-out. The integrated voice-enabled solution is now available for laboratories seeking to modernize their pathology operations.
• AIxMedcoreTechnology or Integration · 30 May 2025Partnership to integrate AIxMed's AIxURO urine cytology diagnostic tool into Lumea's FDA-cleared digital pathology platform for the U.S. urology market. AIxURO uses The Paris System to identify suspicious and atypical cells from non-invasive urine samples, aiming to improve bladder cancer diagnostic accuracy and reduce reliance on invasive procedures like cystoscopies. The partnership expands Lumea's AI offerings and provides AIxMed access to Lumea's established digital pathology ecosystem serving a significant portion of the U.S. urology market.
• PaigecoreTechnology or IntegrationAI partner integrated into Lumea's open AI ecosystem, providing computational pathology AI tools for prostate cancer and other applications directly within the diagnostic workspace.
• MindpeakcoreTechnology or IntegrationAI partner integrated into Lumea's open AI ecosystem, providing computational pathology AI tools directly within the diagnostic workspace.
• AIRA MatrixcoreTechnology or IntegrationAI partner integrated into Lumea's open AI ecosystem, providing computational pathology AI tools directly within the diagnostic workspace.
• GI AllianceflagshipStrategic or Co-development PartnerGI Alliance, the nation's largest GI network, selected Lumea's Viewer+ to power their digital pathology transition. This represents a flagship partnership with the leading GI network in the United States.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Paige.AI: Paige builds AI-enabled digital pathology software for cancer diagnostics, including an FDA-authorized prostate cancer detection tool. Directly comparable to Lumea in serving pathology labs with whole-slide-image workflows and AI integrations; Paige is also a partner in Lumea's marketplace.
• Proscia: Proscia offers a digital pathology platform (Concentriq) used by pathology labs and life sciences organizations for case management, AI integration, and image analysis. Competes head-to-head with Lumea's IMS Viewer+ and BxLink in enabling clinical and research workflows.
• Ibex Medical Analytics: Ibex develops AI-powered decision-support tools for pathology (e.g., Galen Prostate, Galen Breast) deployed across pathology networks. Directly comparable as an AI-pathology vendor whose tools integrate into digital pathology workflows similar to Lumea's partner ecosystem.
• PathAI: PathAI provides AI-driven pathology solutions for both clinical diagnostics and biopharma research, including integrated digital pathology workflow tools. Comparable to Lumea in advancing AI-augmented primary diagnosis and partnering with pathology labs.
• Indica Labs: Indica Labs provides HALO and HALO AI digital pathology image analysis software used by clinical and research pathology labs worldwide. Comparable to Lumea in offering enterprise image-management and AI-integration capabilities for pathology workflows.
• Gestalt Diagnostics: Gestalt Diagnostics offers a digital pathology workflow platform (PathFlow) integrating whole-slide imaging, LIS, and AI for pathology labs. Directly comparable to Lumea's IMS Viewer+ and BxLink in providing an integrated viewer and case-management solution.

Broad incumbents

• Philips (Digital Pathology): Philips IntelliSite Digital Pathology Solution is an established, broad-line enterprise offering used by large hospital systems. Comparable to Lumea in FDA-cleared whole-slide imaging and LIS integration, but as part of Philips' wider healthcare portfolio rather than a specialty-focused platform.
• Leica Biosystems (Aperio): Leica Biosystems, through its Aperio platform, is one of the most entrenched digital pathology scanner and software providers globally. Comparable in providing FDA-cleared viewing and workflow tools, though as a broad-line incumbent with hardware-heavy offerings.
• Hamamatsu Photonics (NanoZoomer): Hamamatsu's NanoZoomer whole-slide scanners and NDP.view software are widely deployed in pathology labs. Comparable to Lumea's imaging-infrastructure stack, though as a hardware-led incumbent rather than a specialty workflow platform.
• Roche (Ventana Digital Pathology): Roche's Ventana digital pathology business provides scanners, workflow software, and AI applications for pathology labs. Comparable in offering end-to-end clinical pathology workflows, though as part of Roche Diagnostics' large IVD portfolio rather than a specialty-focused entrant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/LUMEA_DDx
• YouTubeyoutube.com/channel/UCupd8kiZthw7J5KyUV8NUAA
• LinkedInlinkedin.com/company/lumea
• Instagraminstagram.com/lumeadigital

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumea